In addition, while at present, the detection of CHIP occurs in the course of evaluation of possible hematologic malignancy, during molecular analysis of a solid neoplasm, or after hematopoietic stem cell transplantation, trials will have to expand eligibility algorithms since the overarching goal is to learn about the benefits of atherogenesis prevention or modification in cohorts with normal projected life expectancy, rather than solely in patients with cancers who may not survive long enough to manifest clinical ASCVD. This evidence concerns the gene STUB1 and cancer.